Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

First phase III MS results reported for Novantrone

Sep. 15, 1998

Cerebrus enters into collaborative agreement with Lilly for CEB-1555

Sep. 15, 1998

Scios will copromote SmithKline Beecham's SSRI

Sep. 15, 1998

Pierre Fabre describes pharmacological profile of F-11440 -- new high-efficacy 5-HT1A agonist

Sep. 15, 1998

Potent mGluR1/mGluR5 receptor antagonist presented by Lilly at EFMC symposium

Sep. 15, 1998

SmithKline Beecham research leads to discovery of potent and selective 5-HT7 antagonists

Sep. 15, 1998

F-12682: new 5-HT1B/1D receptor inverse agonist for depression

Sep. 15, 1998

Interneuron receives U.S. patent protection for stroke Rx

Sep. 15, 1998

Capsazepine attenuates inflammation-induced hyperalgesic responses

Sep. 15, 1998

Phase II trial of revolutionary migraine treatment completed ahead of schedule

Sep. 14, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 17, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...